If you would like information regarding products from AstraZeneca, please call 1-888-692-9737, Monday through Friday, 8:30 am to 8:30 pm ET, excluding holidays.
The AZ TouchPoints Web site gives you direct access to AstraZeneca services and support. Here, you can easily find online sample ordering, formulary information, and patient education materials for select AstraZeneca medicines. Go to About AZ TouchPoints
The majority of patients with prescription drug coverage for NEXIUM, including Medicare Part D patients, pay $1 or less per day*†1
*Individual out-of-pocket costs may vary.
The majority of NEXIUM prescriptions written require no prior authorization‡§2
‡Individual plans may vary.
†Source: Wolters Kluwer Health, Dynamic Claims, October 2008 through September 2009 (last accessed November 24, 2009). Based on monthly out-of-pocket retail pharmacy costs for commercial insurance and Medicare Part D standard eligible patients. Excluding claims from Medicare Part D low-income subsidy and dual-eligibles, cash (uninsured), and Medicaid, the percentage of beneficiaries paying $30 or less per month in out-of-pocket costs ranged from 54.97% to 62.66% during the 12-month period of October 2008 through September 2009. Data included claims covering 4100 plans.
§Source: Wolters Kluwer Health, Dynamic Claims, July through September 2009. Database included over 1 million NEXIUM pharmacy benefit claims during the 3rd quarter of 2009 (last accessed December 15, 2009).
Approved Uses
Healing of Erosive Esophagitis (EE)
NEXIUM 40 mg and NEXIUM 20 mg are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed EE.
Maintenance of Healing of EE
NEXIUM 20 mg is indicated to maintain symptom resolution and healing of EE. Controlled studies did not extend beyond 6 months.
Symptomatic GERD
NEXIUM 20 mg is indicated for the treatment of heartburn and other symptoms associated with GERD.
Pediatric Use
NEXIUM is indicated for the short-term treatment (up to 8 weeks) of GERD (symptomatic GERD and healing of EE) in patients 1 to 17 years of age. Pediatric use is supported by extrapolation of results from studies that supported the approval for NEXIUM for adults and safety and pharmacokinetic studies performed in pediatric and adolescent patients.
Effectiveness has not been demonstrated in patients less than 1 year of age. Safety and effectiveness for other pediatric uses have not been established.
Important Safety Information
NEXIUM® (esomeprazole magnesium) is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles
In adult patients, the most frequently reported adverse events (AEs) with NEXIUM include headache, diarrhea, and abdominal pain
In pediatric patients 1 to 17 years of age, the most frequently reported AEs with NEXIUM include headache, diarrhea, abdominal pain, nausea, and somnolence
Symptomatic response to therapy does not preclude the presence of gastric malignancy
Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which NEXIUM is an enantiomer
As with all PPIs, patients treated concomitantly with warfarin may need to be monitored for increases in INR and prothrombin time. Like other PPIs, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts, and digoxin)
Concomitant use of NEXIUM and atazanavir or nelfinavir is not recommended because the plasma concentrations and therapeutic effects of those antiretroviral drugs may be reduced
NEXIUM may increase the plasma levels of saquinavir. Dose reduction of saquinavir should be considered
NEXIUM should be used only for the conditions, dosages, and durations specified in the Prescribing Information. Dosing for adults and pediatrics is provided in the Prescribing Information
(PDF – 303 KB) for NEXIUM.
